Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
adverse databases » jader databases (Expand Search)
access databases » scopus databases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
adverse databases » jader databases (Expand Search)
access databases » scopus databases (Expand Search)
-
1
-
2
-
3
-
4
-
5
Data Sheet 1_The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases.docx
Published 2025“…This study aims to assess the AE profile of azacitidine by utilizing data from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and WHO-VigiAccess databases.…”
-
6
-
7
-
8
-
9
-
10
-
11
-
12
Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease)).
Published 2025“…<p>Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease)).…”
-
13
-
14
Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease).
Published 2025“…<p>Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease).…”
-
15
Inotodiol decreases clone formation in HCC cells.
Published 2025“…Animal studies demonstrated that inotodiol possessed the ability to suppress tumor growth in nude mice models, at the same time, there was no significant impact on the body weight and organs of the mice. …”
-
16
-
17
-
18
-
19
Image 1_Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials: a descriptive analysis of the WHO-VigiAccess database.jpeg
Published 2025“…This study assessed ADRs associated with anti-fibrotic agents as reported in the World Health Organization (WHO) VigiAccess database and compared the adverse reaction characteristics of these agents for optimizing therapeutic strategies.…”
-
20
HFD decreases intermediate-term memory.
Published 2025“…(C) Food intake was not significantly different between ND- and HFD-fed flies during the 1 hour. …”